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Objectives: The use of biologics such as infliximab has dramatically improved the treatment 
of rheumatoid arthritis (RA). However, factors predictive of therapeutic response need to be 
identified. A proteomic study was performed prior to infliximab therapy to identify a panel of 
candidate protein biomarkers of RA predictive of treatment response. 
Methods: Plasma profiles of 60 RA patients (28 non-responders ACR 20 negative and 32 
responders ACR 70 positive to infliximab) were studied by SELDI-TOF-MS technology on 
two types of arrays, an anion exchange array (SAX2) and a nickel affinity array (IMAC3-Ni). 
Biomarker characterization was carried out using classical biochemical methods (purification 
by ammonium sulfate precipitation or metal affinity chromatography) and identification by 
MALDI-TOF analysis. 
Results: Two distinct protein profiles were observed on both arrays and several proteins were 
differentially expressed in both patient populations. Five proteins at 3.86, 7.77, 7.97, 8.14 and 
74.07 kDa were overexpressed in the non-responder group, whereas one at 28 kDa was 
increased in the responder population (sensitivity > 56%, specificity > 77.5%). Moreover 
combination of several biomarkers improved both the sensitivity and specificity of the 
detection of patient response to over 97%. The 28 kDa protein was characterized as 
apolipoprotein A-I and the 7.77 kDa biomarker was identified as platelet factor 4.  
Conclusions: We characterized six plasma biomarkers, enabling the detection of patient 
response to infliximab with high sensitivity and specificity. Apolipoprotein A-1 was predictive 
of a good response to infliximab, whereas platelet factor 4 was associated with non-responders. 
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Prevalence of rheumatoid arthritis (RA) varies between 0.3 and 0.8% in European countries.[1] 
Joint invasion and destruction are mainly mediated by inflammatory cells, cytokines and 
proteolytic enzymes. The heterogeneity of pathological manifestations, disease course, and 
response to treatments suggests that several subtypes of RA exist, especially at a molecular 
level.  
Early referral, diagnosis and initiation of treatments to control tissue damage and structural 
progression are highly recommended, considering the disease’s high propensity towards joint 
destruction, even during periods of clinical remission.[2] Although classical treatments are still 
used [3, 4], a radical new approach to RA treatment is now available with the use of the 
biological therapies, such as tumor necrosis factor α (TNFα) inhibitors (etanercept, infliximab, 
adalimumab), anti-CD20 antibodies (rituximab), interleukin-1 (IL-1) receptor antagonists 
(anakinra) and an inhibitor of T lymphocyte costimulation (abatacept). Almost 70% of treated 
patients respond to these therapies, but for unknown reasons, approximately one-third of RA 
patients do not respond [5]. Indeed, the currently used markers reflecting bone and cartilage 
turnover [6] are few and inaccurate, and no predictive factor of treatment resistance has been 
identified. Discovery of biomarkers for diagnosis, prognosis and disease monitoring [7] is 
necessary. 
In order to identify proteins predictive of a treatment response, we chose to study the plasma 
proteome (i.e. the whole protein content) of RA patients by the technology SELDI-TOF-MS 
(Surface Enhanced Laser Desorption/Ionization – Time Of Flight Mass Spectrometry) 
developed by Ciphergen Biosystems, Inc..[8, 9] This method has allowed characterization of 
numerous biomarkers for many diseases [10-12], particularly cancer.[13-16] 
Concerning RA, a first SELDI-based study on 12 synovial fluid samples characterized an RA 
biomarker absent in osteoarthritis patients, the pro-inflammatory S100A8 protein.[17] More 
recently the same protein was identified in a larger survey comparing serum protein profiles of 
RA and non-inflammatory control samples.[18]  
 4
In our study, we used this SELDI-TOF-MS technology to characterize biomarkers predictive of 
an anti-TNFα therapy response in RA patients. Protein profiles were performed on plasma 
specimens taken prior to the start of infliximab treatment, from patients that were further 
evaluated as non-responders (ACR 20 negative) or responders (ACR 70 positive) to the 
therapy. Several biomarkers were isolated and were highly correlated with the infliximab 
response both independently or when associated in a decision tree algorithm. Moreover, 
corresponding proteins were identified using classical biochemistry techniques. 
 
 
PATIENTS AND METHODS 
 
Patients and study protocol 
Patients with a RA diagnosis according to ACR (American College of Rheumatology) criteria 
were recruited in four university hospitals from the Rhône-Alpes area. All patients had disease 
duration of at least 6 months, had never received anti-TNFα therapy before inclusion and had 
no active or latent bacterial, fungal or viral infection at the time of enrolment. Blood was 
withdrawn on a spray-coated K2EDTA tube before the first infliximab infusion and plasma 
aliquots were stored at -80°C. Patients then received the same infliximab treatment as 
previously described [19] and clinical outcome was assessed at week 30. Among the 60 
recruited patients, 28 were ACR 20 negative (non-responders), whereas 32 were ACR 70 
positive (responders). Differences between both populations of each classical parameter 




The plasma protein profile was investigated with the SELDI-TOF-MS method developed by 
Ciphergen Biosystems, Inc (Fremont, CA), that associates a first phase of protein fractionation 
on chips with distinct chromatographic surfaces (cationic, anionic, hydrophobic …) to a second 
detection step of protein molecular weight by mass spectrometry after laser desorption. We 
used an anion exchange array (SAX2) and a nickel affinity chip (IMAC3-Ni). Firstly, the 
sample protein concentration was evaluated using the Bradford method.[20] For the SAX2 
array, 5 µl of plasma diluted to a final concentration of 0.7 µg/µl in a washing / loading buffer 
(10 mM Tris, 0.1% Triton X100 pH 7) was loaded twice in duplicate for a 30 min incubation 
period at room temperature. Then spots were washed twice with 5 µl of washing buffer, twice 
with 5 µl of the same buffer without Triton X100 and finally with 5 µl of 10 mM Hepes pH 7. 
For the IMAC-Ni array, 20 µl of plasma was mixed with 30 µl of a denaturation buffer (50 
mM Tris, 8 M urea, 1% CHAPS pH 7.4) for 15 min at +4°C with frequent agitations, and 5 µl 
of this protein solution diluted in the washing / loading buffer (PBS, 0.5 M NaCl, 0.1% Triton 
X100 pH 7.3) to 0.7 µg/µl was applied on each spot previously activated with 100 mM NiSO4. 
Incubation and washing steps were performed as previously described, using the IMAC3 buffer 
with (first two washes) or without Triton X100 (last two washes). Then 0.8 µl of saturated 
sinapinic acid in 0.5% trifluoroacetic acid, 50% acetonitrile was applied twice on each spot and 
chips were analyzed on the ProteinChip® reader (model PBSII). Mass data processing was 
performed with the Ciphergen ProteinChip® software 3.1 and intensities, (height from 
baseline), of characterized proteins were compared in each group using the Mann-Whitney U-
test. ROC (Receiver Operating Characteristic) curve analyses were performed to measure the 
diagnostic potential of each biomarker and correlations between variables (biomarkers and 
clinical data) were evaluated using the Spearman rank test. Finally, CART (Classification and 




Protein purification and identification 
Apolipoprotein A-I was purified from 300 µl of responder plasma by protein precipitation with 
50% ammonium sulfate. After centrifugation at 14000 g for 10 min, 5 µl of supernatant (6.35 
µg) was loaded on a 15% SDS-PAGE gel which was further stained with Coomassie blue R-
250. The only band revealed at about 28 kDa was excised from the gel, trypsin-digested and 
sequenced by LC-MSMS (liquid chromatography-tandem mass spectrometry).  
 
Platelet factor 4 (PF4) was purified from 5.2 ml of non-responder plasma on a cobalt-based 
affinity resin. After washings, the matrix-bound proteins were desorbed with 6 ml PBS 1X 
containing 20 mM imidazole and 0.5 M NaCl. This specific eluate was dialyzed overnight in 
distilled water, lyophilized and the resuspended powder was finally loaded on an 18% SDS-
PAGE gel. A thick Coomassie blue R-250 stained band between 6 kDa and 14 kDa was 
sequenced by LC-MSMS as previously described. As results were not conclusive, we set up an 
ELISA for platelet factor 4 in order to deplete the column specific eluate from the 7,769 Da 
biomarker. Then 100 µl of eluate diluted twice in 2% bovine serum albumin (BSA) was 
incubated on a 96-well plate for 2 h at room temperature in wells previously coated with 1, 2 or 
10 µg of monoclonal anti-human PF4 antibody (R&D Systems, Lille, France). Next 2 µl of 
supernatant was loaded on a normal phase NP20 chip which was analyzed on the ProteinChip® 
reader. Results were expressed as a ratio of the intensity of the 7,769 Da peak to the BSA peak 
value in order to overcome possible loading discrepancies and significance was assessed using 






Blood protein profiles of RA patients before the start of infliximab treatment 
Characteristics of enrolled patients are summarized in table 1. Both populations were similar in 
terms of patient identity (age and sex), RA characteristics (disease duration, number of swollen 
and tender joints) and biological parameters such as rheumatoid factor (RF), C-reactive protein 
(CRP) and erythrocyte sedimentation rate (ESR), demonstrated that in this panel as well as in 
general RA population, no classical marker of RA severity and aggressiveness could predict 
the patient response to an anti-TNFα therapy.  
 
Table 1: Demographic characteristics of patients at inclusion 
Group characteristics ACR 20 negative ACR 70 positive 
Number 28 32 
Age (years) 53 (37.7-61.3) 58 (31-78.15) 
Women (%) 78 90 
Disease duration (years) 11,5 (5-31.45) 12.5 (4.95-28.9) 
RF positive (%) 75 95 
CRP level (mg/liter) 25.65 (0.85-58.05) 13.5 (2.85-45.1) 
ESR (mm first hour) 34 (7.4-76.35) 34 (15.9-78.4) 
Number tender joints 11 (3.55-21) 13 (5.75-27) 
Number swollen joints 4.5 (0.85-10) 6 (0.95-14) 
 
Values correspond to medians + 5th and 95th percentiles, except for sex and RF expressed as 
percentages. RF = Rheumatoid Factor; CRP = C-Reactive Protein; ESR = Erythrocyte 
Sedimentation Rate. 
 
Two distinct protein profiles were obtained through plasma analysis on the SAX2 and IMAC-
Ni arrays (fig 1A&B). Moreover, duplicate loadings of samples showed a similar protein 
pattern, characterizing the reproducibility of our experimental procedure (data not shown). 
Several proteins were found to be differentially expressed in both patient populations: only one 
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small protein at 3.86 kDa was characterized on the SAX2 anion exchange array whereas five 
distinct markers at 7.77, 7.97, 8.21, 28.0 and 74.07 kDa were identified from the IMAC-Ni 
affinity array (table 2). All biomarkers were significantly increased in the non-responder 
population, except the 28.0 kDa protein which was overexpressed in responders, and they 
discriminated both populations with an overall high specificity (>77.5%), a lower sensitivity 
(>56%) and an AUC ranging from 0.761 to 0.846, depending on the biomarkers. Correlation 
analyses between the six biomarkers showed that only the 3 proteins around 8 kDa isolated on 
IMAC-Ni were strongly positively related: 7.77 and 7.97 (r=0.587, p<0.0001), 7.77 and 8.21 
(r=0.597, p<0.0001), and 7.97 and 8.14 (r= 0.869, p<0.0001). 
 
Table 2: Characterization of plasma biomarkers for infliximab treatment response in RA 
 Peak intensity (mean ± SD)       
Marker 
(kDa)  




17.22 ± 7.23 
 


















20.50 ± 8.69 
15.20 ± 5.94 
17.38 ± 6.31 
1.88 ± 0.94 
8.55 ± 4.34 
 
11.05 ± 6.23 
9.82 ± 4.44 
11.81 ± 4.76 
3.74 ± 2.16 
































NR = Non-Responder; R = Responder; SD = Standard Deviation; Spec = Specificity; Sens = 
Sensitivity; AUC = Area Under the Curve; p was calculated using the Mann-Whitney test 
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The entire protein profiles of both populations were then compared in a multivariate CART 
analysis. The best tree, obtained with the IMAC3-Ni proteomic profile, comprises five nodes: 
following the path according to the node value (protein peak intensity) leads to a terminal node 
classifying the patient in either of the two populations. This classification tree predicts 
infliximab response in this population with a specificity of 97.5% and a sensitivity of 97.1% 
(fig 2). Combining proteomic profiles with clinical data (CRP, ESR, disease duration and 
number of swollen or tender joints) or using both the SAX2 and IMAC3 profiles did not 
improve specificity and sensitivity. Moreover three proteins of the tree at 7.77, 8.21 and 28 
kDa are individually highly discriminating (table 2). Box plot representation of individual peak 
intensities of these proteins, showed a tiny overlap of values between both populations (fig 3A, 
B&C), especially for the 7.77 and 28 kDa biomarkers. We then focused on the characterization 
of these two biomarkers.  
 
Purification and identification of the 7.77 and 28.0 kDa biomarkers 
The 28 kDa biomarker was first purified by ammonium sulfate precipitation: although part of 
the protein was precipitated in the pellet, a nearly pure band was recovered at about 28 kDa in 
the supernatant as shown on an SDS-PAGE gel (fig 4A). Loading supernatant on an IMAC3-
Ni chip confirmed this protein to be the previous identified biomarker at m/z 27,976 (data not 
shown). Finally the sequencing of this protein by LC-MSMS identified it undoubtedly as 
apolipoprotein A-I (on-line table 1). Correlation analysis showed that this biomarker was 
independent of clinical variables. 
Identification of the 7.77 kDa required more steps. A first purification step on an IMAC-based 
column allowed the isolation in the specific eluate of one main protein at m/z 7,769 
contaminated by faint amounts of 3 proteins between 8 and 9 kDa, as characterized on the 
IMAC-Ni and NP20 arrays (data not shown and fig 4B). Fractioning this sample on an SDS-
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PAGE revealed a thick band around 8 kDa that was sequenced by LS-MSMS: several proteins 
were characterized, among which platelet factor 4 (PF4, or CXCL4) was the most represented 
(on-line table 2). Based on previous studies identifying this 7,769 Da protein as mature PF4 
(without the first 31 amino acids of the signal peptide) [22, 23], we tried to deplete the column 
eluate from the biomarker with a homemade PF4 ELISA. The decrease of the peak intensity in 
the supernatant after incubation with anti-PF4 antibodies, evaluated on an NP20 array, was 
proportional to the increase of the amount of antibodies coated in the wells (fig 4B), with a 
significant 44% reduction of the signal for the highest antibody concentration (fig 4C). This 
last experiment formally identified the 7.77 kDa biomarker as platelet factor 4. As previously, 





In this study with SELDI-TOF-MS we characterized several biomarkers closely correlated to 
the response to infliximab therapy in RA patients. Although other clinical and biological 
parameters such as number of inflamed joints, HLA haplotypes or CRP level, can partially 
predict treatment efficiency [7], this is the first time to our knowledge that biomarkers with 
specificity as high as 87.5% independently and 97.5% when associated in a classification tree, 
have been determined. Indeed, these prediction characteristics were obtained for the 
discrimination of two extreme patient groups (ACR 20 negative and ACR 70 positive) and it is 
likely that specificity and sensitivity of these biomarkers will be lower when used on a more 
homogeneous RA population. Six biomarkers between 3.86 and 74.07 kDa were isolated on 
two chromatographic surfaces, suggesting different reactivities of these proteins. The smallest 
one at 3.86 kDa was characterized on an anion array, meaning that this protein is negatively 
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charged at pH 7. The other 5 biomarkers isolated on an IMAC-Ni chip have a specific affinity 
for this metallic ion. Three of these proteins were also recovered in the classification tree built 
from the IMAC-Ni plasma profile, emphasising their importance in the determination of the 
infliximab response. 
 
We focused initially on the 28 kDa protein that is overexpressed in the responder population 
and is also the first node of the decision tree, and we identified it as apolipoprotein A-I. 
Apolipoprotein A-I is the major protein component of HDL (High Density Protein) particles 
and the primary acceptor for cholesterol in extra-hepatic tissues. In RA, several studies have 
reported a decrease of circulating levels of apolipoprotein A-I and HDL-cholesterol in patients 
compared to the general population [24-26], and concentration of both parameters increases 
significantly in patients responding to a DMARD (Disease-Modifying Anti-Rheumatic Drug) 
treatment compared to non-responders.[27] On the other hand, apolipoprotein A-I was highly 
expressed in inflamed RA synovial tissues particularly in perivascular areas containing 
infiltrated T cells and macrophages, but was not detected in normal tissue [28] or in the 
synovium of non-inflammatory RA.[29] Moreover, increased levels of apolipoprotein A-I and 
cholesterol have been measured in RA synovial fluid.[30] As apolipoprotein A-I was reported 
to inhibit the synthesis of the major inflammatory cytokines TNFα and interleukin-1β by 
blocking direct contact between T lymphocytes and monocytes [31], increased levels of this 
protein in synovial tissue could modulate inflammation and disease evolution by controlling 
interactions between immune cells and then cytokine production.[28, 32] This specific function 
as a “negative” acute phase protein is also emphasised in a study reporting that patients with 
lower levels of apolipoprotein A-1 develop more systemic inflammatory response syndrome 
criteria.[33] 
Finally, it has been recently shown in a retrospective study among blood donors (n=1078) who 
later developed RA (n=79) that the lipid profile was perturbed at least 10 years prior to the 
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onset of symptoms, especially the HDL-cholesterol value that was significantly decreased.[34] 
The authors suggested that this specific lipid profile may be favourable to the onset of RA or 
the presence of a constant high inflammatory state due to low levels of HDL-cholesterol. In our 
study, we demonstrated that high pre-treatment levels of apolipoprotein A-I were predictive of 
a good response to infliximab. This increased initial concentration may favour the response to 
anti-TNFα treatment, via the decrease of chronic inflammation, by inhibiting cytokine release 
and potentiating the efficiency of therapy in a synergistic way. 
 
The second biomarker we focused on was overexpressed in non-responder patients and was 
identified as platelet factor 4 (PF4) (or CXCL4). This chemokine specific for platelet α-
granules exerts multiple functions in several physiological processes.[35] In RA, several 
studies reported an increase of PF4 in patient synovial fluid [36, 37] and elevated plasma levels 
in patients with cutaneous vasculitis.[38] In our study, the increase in plasma PF4 was 
correlated to a non-response to infliximab, and the same rise was recently shown in sera of 
Crohns disease patients who had not responded to infliximab therapy.[39] Two of its 
coagulation-unrelated functions may explain this result: PF4 was reported to induce 
degranulation of TNFα-primed neutrophils [40] and to inhibit monocyte apoptosis.[41] A high 
PF4 concentration may increase the inflammatory response by potentiating the pro-
inflammatory functions of neutrophils and monocytes, that may counteract the efficiency of an 
anti-TNFα therapy. 
In this proteomic study that investigated the plasma protein profile of RA patients who were 
either responders or non-responders to infliximab therapy, we identified two biomarkers 
(apolipoprotein A-I and PF4) that may be key elements for RA treatment monitoring. Firstly, 
these proteins are involved in RA physiopathology and may be associated with specific clinical 
situations such as inflammation or vasculitis and secondly, both are strongly correlated with 
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and without clinical response to infliximab treatment. However, these biomarkers need to be 
validated in a larger cohort of patients and to be evaluated for determination of intermediate 
treatment response assessed by the ACR score (ACR50) or more linearly by the Disease 
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Figure 1: Representative SELDI-TOF-MS plasma profiles on SAX2 and IMAC3-Ni 
arrays 
Plasma proteome of RA patients was analyzed by SELDI-TOF-MS with different laser 
intensities to characterize large (A) and smaller (B) proteins. Spectra showed relative intensity 
of each protein according to its mass/charge (m/z) value. Some peak intensities are marked in 
italic typing. 
 
Figure 2: Decision tree built from IMAC3-Ni protein profile 
CART analysis was performed on the whole proteome peaks characterized on the IMAC-Ni 
array. The intensity (I) of each node corresponding to a protein will draw a path for each 
patient leading to a terminal node, classifying the patient as a responder (R) or a non-responder 
(NR) 
 
Figure 3: Relative peak intensities of the 7,769 Da (A) the 8,210 (B) and the 27,976 Da 
biomarkers in the responder (R) and non-responder (NR) populations 
The box represents the interquartile range, the line across the box is the median and the 
whiskers represent the 5th and 95th percentiles. 
 
Figure 4: Identification of the 27,976 Da and the 7,769 Da biomarkers 
(A) Proteins from a responder plasma were precipitated with 50% ammonium sulfate and after 
centrifugation, 1 µl of pellet (lane 2 – 42.63 µg), 5 µl of desalted supernatant (lane 3 - 6.35 µg) 
and 1 µl of pure plasma (lane 1 – 77.43 µg) were loaded on a 15% SDS-PAGE gel. The 28 kDa 
band in the supernatant (circled on the gel) was identified by LC-MSMS as apolipoprotein A-I. 
(B) The 7,769 Da biomarker purified on a cobalt-based IMAC was incubated with coated anti-
 21
PF4 monoclonal antibodies (1 to 10 µg / well) and after a 2 h incubation period, supernatant 
was loaded on an NP20 array. (C) The intensity of this protein peak (in parenthesis on spectra) 
normalized to the BSA signal decreased while amount of coated antibody increased (* p=0.022 
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